Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENG Block vs Analgosedation for Hip Fracture Positioning
NCT05079087Unknown
- Sponsor
- Azienda Sanitaria dell'Alto Adige
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine and dexamethasone in Pertrochanteric fracture of femur (2 arms), sponsored by Azienda Sanitaria dell'Alto Adige. Primary endpoint: Change of the numerical rating scale for pain (NRS) during movement of the affected limb at 18 hours. Status: unknown.
02
Drugs
ropivacainedexamethasone
03
Conditions
Pertrochanteric fracture of femur
Beyond the preview
Go deeper on NCT05079087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079087.